中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (12): 849-852.doi: 10.12144/zgmfskin202212849

• 论著 • 上一篇    下一篇

度普利尤单抗治疗中重度特应性皮炎16周疗效和安全性分析

李萌萌,黎静宜,刘青锋,刘友庆,李薇   

  1. 四川大学华西医院皮肤科，四川成都，610041
  • 出版日期:2022-12-15 发布日期:2022-10-26

Clinical efficacy and safety of dupilumab in the treatment of moderate and severe atopic dermatitis for 16 weeks

LI Mengmeng, LI Jingyi, LIU Qingfeng, LIU Youqing, LI Wei   

  1. Department of Dermatovenereology, West China Hospital of Sichuan University, Chengdu 610041, China
  • Online:2022-12-15 Published:2022-10-26

PDF (PC)

198

摘要： 目的：评价度普利尤单抗治疗中重度特应性皮炎（AD）的疗效与安全性。方法：回顾性分析2020年6月19日至2021年11月19日度普利尤单抗治疗的18例中重度AD患者的临床及实验室资料，评价其疗效及安全性。选择湿疹面积及严重度指数（EASI）和峰值瘙痒数字评价量表（NRS）评价 AD患者的皮损严重程度及瘙痒情况。 结果：18例患者治疗16周后EASI（4.78±4.80）和 NRS评分（2.39±2.43）较治疗前（17.91±10.82；6.78±2.05）均明显下降，差异均有统计学意义（均P＜0.05），EASI 50，EASI 75 和EASI 90 的达标率在治疗4周后分别为50%、16.7%、5.6%，治疗16周后分别为94%、55.6%、27.8%。7例患者（38.9%）出现了不良反应，均为轻度，最常见的不良反应为鳞屑增多。结论：度普利尤单抗治疗中重度AD疗效好且安全性高。

关键词: 特应性皮炎, 度普利尤单抗, 白细胞介素4, 安全性

Abstract: Objective: To evaluate efficacy and safety of dupilumab in the treatment of moderate and severe atopic dermatitis (AD). Methods: A retrospective study was conducted among 18 patients with moderate to severe AD treated by dupilumab from June 19, 2020 to November 19, 2021. The clinical and laboratory data were analyzed and the efficacy and safety were accessed. The severity of skin lesions and itching were evaluated by Eczema Area and Severity Index (EASI) and Peak Itching Digital Evaluation Scale (NRS). Results: At week 16, the patients' EASI (4.78±4.80) and NRS (2.39±2.43) were significantly decreased than those before treatment (17.91±10.82, 6.78±2.05) (Ps<0.05). The qualified rates of EASI 50, EASI 75 and EASI 90 were 50%, 16.7% and 5.6% respectively after treated for 4 weeks, and 94%, 55.6% and 27.8% for 16 weeks. Seven patients (38.9%) had mild adverse reactions, and the most common adverse reaction was scaling. Conclusion: Dupilumab is effective and safe in the treatment of moderate and severe AD.

Key words: atopic dermatitis, Dupilumab, Interleukin-4, safety